New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists

Amgen Inc.Each year, hundreds of undergraduate students from across the United States (U.S.) and Europe participate in the Amgen Scholars Program to gain hands-on laboratory experience under renowned faculty members at the world's leading universities. Now, the Amgen Scholars - past, present and future - will have exclusive access to the online Amgen Scholars Community.

"The new Web site is designed to connect, engage and inspire Amgen Scholars on a global level by bringing together participants from diverse backgrounds and wide-ranging scientific career aspirations," said Jean J. Lim, president of the Amgen Foundation. "We hope that the online community will enrich the experience for all Amgen Scholars, not only during the program, but throughout their future careers in science."

The new Web site, launched in partnership with The Scientist, a leading life sciences magazine, allows current Amgen Scholars and alumni to login and access tools aimed at helping them build professional networks and read the latest science and career news. Through the use of interactive polls, message boards, personal profiles and blogs, users can discuss their participation in the program and various science-related topics such as graduate education and career paths in research. Others interested in the program can also view past participant and faculty mentor profiles and read excerpts of student blogs from the online community in the publicly-accessible section of the site.

2010 Amgen Scholars Program Applications Now Available
Established in 2006, Amgen Scholars is a $27.5 million initiative that provides undergraduates with the opportunity for hands-on research at some of the world's leading institutions. The opportunity to work with top academic scientists is a cornerstone of the program, with participating universities seeking to match students with faculty members who will both inspire and challenge them. In addition, the U.S. and Europe programs each host a three-day symposium allowing students to share their summer research projects and hear firsthand from leading industry and academic scientists.

To date, more than 800 undergraduates have participated in the Amgen Scholars Program. Considered among the most competitive summer research programs in the U.S., several Amgen Scholar alumni have gone on to pursue doctorates at leading universities with some being selected for premier fellowships including the Rhodes Scholarships.

In the U.S., the host universities are California Institute of Technology; Columbia University/Barnard College; Howard University; MIT; Stanford University; University of California, Berkeley; UCLA; University of California, San Diego; University of California, San Francisco; and University of Washington. In Europe, the participating universities are the University of Cambridge; Karolinska Institute; and Ludwig-Maximilians-University.

Financial support for students is a critical component of the U.S. and Europe programs, which aims to ensure that eligible students, regardless of their financial status, are able to participate. Please note that details vary by host university.

For more information about Amgen Scholars including eligibility criteria and applications, please visit www.amgenscholars.com.

About the Amgen Foundation
The Amgen Foundation (www.amgen.com/citizenship/overview.html) seeks to advance science education; improve patient access to quality care; and strengthen the communities where Amgen staff members live and work. Since 1991, the Foundation has made $130 million in grants to nonprofit organizations throughout the United States, Puerto Rico and Europe that impact society in inspiring and innovative ways, and those that provide disaster relief efforts internationally.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

How old antibiotic compounds could become tomorrow…

As the fight against drug-resistant infections continues, University of Leeds scientists are looking back at previously discarded chemical compounds, to see if any could ...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Roche purchases shares in tender offer for Ignyta…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. today announced that Roche's wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares v...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]